Integrative analysis of genotypes and clinical features of 120 DCM patients revealed that TTN truncation mutations, which account for 12%–25% of DCM, were a favorable prognosis group with reverse left ventricular remodeling (restoration of systolic function) in response to medical therapy, whereas LMNA gene mutations, which account for 4%–10% of DCM, were a poor prognosis group without reverse remodeling (16). The gene discussed is LMNA; the disease is familial dilated cardiomyopathy.